Status:
RECRUITING
Brain Connectivity Marker for Alzheimer's Disease
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
The Swedish Research Council
Conditions:
Alzheimer Disease
Eligibility:
All Genders
40-85 years
Brief Summary
The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).
Detailed Description
To achieve this aim, the investigators will perform six different studies that have been designed to achieve the following specific objectives: 1.1. Identify changes of brain connectivity in individu...
Eligibility Criteria
Inclusion
- Inclusion criteria for subjects with subjective cognitive complaints:
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30.
- Absence of cognitive impairment.
- Memory problems reported by the participant/family member.
- Do not fulfill criteria for mild cognitive impairment or dementia.
- Must speak and understand Swedish.
- Inclusion criteria for patients with mild cognitive impairment:
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 24 and 30.
- Impaired memory function.
- Do not fulfill criteria for dementia.
- Must speak and understand Swedish.
- Must have abnormal cerebrospinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
- Specific inclusion criteria for patients with Alzheimer's disease:
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 18 and 28.
- Impaired memory function in addition to impaired executive abilities, language function, visuospatial ability and/or attention/psychomotor speed.
- Meet NINCDS-ADRDA and DSM-IV criteria for probable Alzheimer's disease.
- Must speak and understand Swedish.
- Must have abnormal spinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
Exclusion
- Alcohol or drug abuse.
- Unstable somatic disease or organ failure.
- Refuse to cerebrospinal fluid testing and/or blood sampling, neuropsychological testing, brain imaging, electroencephalogram or magnetoencephalogram.
- In addition, participants who have claustrophobia or some form of metal implant in their body that may interfere with the brain imaging scan will be excluded from the study.
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06874231
Start Date
April 1 2023
End Date
July 31 2027
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Solna, Sweden, 171 64